The Industry
Every year, tens of thousands of beagles are bred, sold, tested on, and killed inside a supply chain designed to be invisible. This page maps the industry — who breeds the dogs, who buys them, who tests on them, how much it costs, and why the system persists despite viable alternatives.
The Supply Chain
Click each step to expand. Five stages from breeding to endpoint — each designed to insulate the next from accountability.
The Players
Breeders (Class A Licensed)
Contract Research Organizations
The Collapse of the US Supply Chain
In 2020, three major companies bred beagles for US laboratories. By mid-2026, only one will remain.
DOJ civil complaint → criminal guilty pleas → $35M penalty → 4,000 beagles rescued. PETA investigation triggered it. National media made it impossible to ignore.
311 DATCP violations. Vet license suspended. Special prosecutor appointment via citizen petition. Settlement avoids criminal charges in exchange for closure. March 2026: 22 beagles rescued in open action.
~23,000 dogs. 20+ USDA violations. Whistleblower photos published 2024. No comparable enforcement action. Near-monopoly on US purpose-bred beagle supply.
The Economics
| Study Type | Duration | Dogs | Cost |
|---|---|---|---|
| Acute toxicology | Single dose + 14 days | 8-16 | ~$150K |
| 90-day subchronic (OECD 409) | 90 days | 32-48 | ~$320K |
| Chronic toxicology | 6-12 months | 40-64 | ~$1M+ |
| Cardiovascular safety (telemetry) | Crossover design | 4-8 | ~$200K |
| Reproductive/developmental (DART) | Multi-generation | 48-96 | ~$500K-$1.5M |
| Inhalation toxicology | 28-90 days | 32-48 | ~$400K-$800K |
Why Beagles?
Six traits that make beagles the research industry's preferred non-rodent species. Click any trait to see how it shows up in practice.
The Global Trade
The beagle trade is global. Marshall BioResources operates in at least 7 countries. Before it was disrupted in 2023, the Copenhagen air route alone moved 6,000+ beagles on SAS passenger flights from the US to seven European countries. The EU uses approximately 5,000 dogs per year in research. The UK adds ~2,600 procedures involving dogs annually, with 97.3% being beagles — the only jurisdiction that tracks breed.
The Regulatory Lock-In
The industry persists not because animal testing is scientifically superior, but because 60 years of regulatory precedent have created a self-reinforcing cycle: guidelines require dog data → labs use dogs → data accumulates → reviewers expect dog data → guidelines reference dogs. The FDA Modernization Act 2.0 (2022) broke the legal mandate, but the cultural and institutional inertia remains.
What's Changed
- FDA Modernization Act 2.0 (2022) — removed animal testing mandate
- FDA Modernization Act 3.0 (2025) — passed Senate unanimously
- FDA announced phase-out plan — animal testing to become “the exception” within 3-5 years
- NIH permits rehoming costs on research grants (2025)
What Hasn't Changed
- ICH S7B still references dog cardiovascular models
- CiPA (computational alternative) still not fully accepted after 10+ years
- Historical control databases are built on beagle data — switching species loses baseline
- Charles River reports increased in vivo demand in 2025 despite NAM investments
The Beagle Supply Chain
From breeding facility to necropsy table — the pipeline that uses 42,880 dogs per year in the US alone
Breeders
Class A LicensedMarshall BioResources (~23,000 dogs), Ridglan (closing), Envigo (closed)
1 major US breeder remaining after July 2026
Transport
Ground & AirClimate-controlled vans, cargo on passenger flights (Copenhagen route disrupted 2023)
No habituation to transport stress (controlled studies)
CROs
Contract Research OrgsCharles River ($4B), Labcorp, Altasciences (1,931 dogs), Inotiv, SNBL
9,099 dogs at Charles River alone (FY2022)
Pharma
The End CustomerMerck, Zoetis, Bayer (confirmed via Liberty Research). Most contracts confidential.
Dog cost is <0.2% of study cost — invisible in budgets
Regulators
FDA, EMA, PMDAAccept the data, set the rules, rarely inspect. Historical controls built on beagle data.
60+ years of beagle baseline data creates lock-in
Endpoint
~95% EuthanizedNecropsy required for regulatory histopathology. 0.4% rehomed (UK data). 17 US states with freedom laws.
The dog is killed so its organs can be examined
Understanding the supply chain reveals where pressure can be applied. The breeder is the most visible target, but the CRO captures most economic value, and the pharma company drives demand while remaining invisible.
Source: USDA APHIS FY2024; CRO SEC filings; DOJ enforcement data; EPA study cost estimates
Go Deeper
Deep investigative profiles of all 5 major CROs with SEC data, USDA numbers, and controversies
Five-stage pipeline from breeding to endpoint. International scope.
Follow the money through breeders, CROs, and pharma companies.
Cost breakdown per dog, per study, per drug program.
Who buys the dogs and how the CRO shield works.
EU, UK, Japan usage. Copenhagen route. Cross-border dynamics.
Marshall, Ridglan, Envigo — full facility hubs with tabs.
The investigations and images that exposed this industry.
Organ-on-chip, computational methods, legislative wins, 5-20 year outlook.